Percheron Therapeutics Limited
PERCF
$0.0025
-$0.0165-86.84%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.95M | 1.95M | 1.95M | 1.63M | 1.33M |
| Total Other Revenue | -689.60K | -348.00K | -6.00K | 224.60K | 450.60K |
| Total Revenue | 1.26M | 1.61M | 1.95M | 1.86M | 1.78M |
| Cost of Revenue | 76.30K | 59.00K | 40.80K | 39.10K | 37.50K |
| Gross Profit | 1.19M | 1.55M | 1.91M | 1.82M | 1.74M |
| SG&A Expenses | 3.05M | 2.86M | 2.65M | 2.36M | 2.07M |
| Depreciation & Amortization | 45.00K | 48.60K | 52.00K | 57.30K | 63.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.58M | 10.71M | 9.77M | 9.35M | 9.01M |
| Operating Income | -10.31M | -9.10M | -7.82M | -7.50M | -7.23M |
| Income Before Tax | -10.36M | -9.13M | -7.82M | -7.50M | -7.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.36 | -9.13 | -7.82 | -7.50 | -7.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.36M | -9.13M | -7.82M | -7.50M | -7.23M |
| EBIT | -10.31M | -9.10M | -7.82M | -7.50M | -7.23M |
| EBITDA | -10.29M | -9.07M | -7.78M | -7.46M | -7.19M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 3.94B | 3.73B | 3.52B | 3.16B | 2.79B |
| Average Diluted Shares Outstanding | 3.94B | 3.73B | 3.52B | 3.16B | 2.79B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |